First malaria vaccine for infants and children moves forward

Innovative malaria vaccine from NYU Langone Medical Center
Innovative malaria vaccine from NYU Langone Medical Center | Courtesy of
Scientists from New York University’s Langone Medical Center have developed a new malaria vaccine that recently received an approval recommendation from the European Medicines Agency to be the world’s first licensed vaccine to protect infants and children from the disease.

Victor and Ruth Nussenzweig are a husband-and-wife team with more than 50 years of work in developing a vaccine against malaria. This breakthrough is the culmination of their efforts.

"Without the work of Ruth and Victor Nussenzweig, we probably would not be at the precipice of a first-ever approved vaccine to prevent malaria," Jeffrey Weiser, chair of the Department of Microbiology at NYU Langone, said. "Malaria is one of the 'ancient plagues of mankind,' affecting regions throughout the world. The Nussenzweigs' commitment to fighting this disease has earned them a rightful place among the leaders in the fields of parasitology and vaccinology. And it is wonderful that they have seen this historic announcement in their lifetime. 

"Many breakthroughs against some of the great health scourges have occurred through research at NYU Langone," Weiser said. "Ruth and Victor carry on the finest traditions of important scientific work that is rooted here."

Organizations in this Story

NYU Langone Medical Center

Want to get notified whenever we write about NYU Langone Medical Center ?
Next time we write about NYU Langone Medical Center, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.